News Centre

Moscow Exchange: MICEX 10 Index Methodology Change

Date 24/07/2018

A new version of MICEX 10 Index Methodology was approved on 6 July 2018 with the following amendments:

• MICEX 10 Index is renamed MOEX 10 Index;
• Timings for index constituents list formulation and disclosure are synchronized with other indices;
• Index calculation formulate is adjusted;
• Index is  to be calculated based on closing prices;
• Some editorial changes are made throughout the text.

Shenzhen Stock Exchange Imposes Restrictions On The Shares Held By Changsheng Bio-technology's Shareholders

Date 24/07/2018

On July 23, CSRC initiated an investigation into Changsheng Bio-technology Co. Ltd. (hereinafter as “the Company”) for suspected illegal information disclosure. On the same day, the Company announced that if the regulatory department finally decides the Company as being involved in material illegal behaviors or being transferred to the public security organ because of the aforesaid investigation, the Company shares would be subject to delisting risk warnings, listing suspension or delisting according to the SZSE Rules Governing Share Listing.

EuroCCP Signs Agreement With Deutsche Börse To Provide CCP Services For Frankfurt Stock Exchange

Date 24/07/2018

Deutsche Börse AG and European Central Counterparty NV (EuroCCP) have signed an agreement, which will govern the project for EuroCCP to gain access to the Frankfurter Wertpapierbörse (FWB), the Frankfurt Stock Exchange.

EBA Updates On Monitoring Of Additional Tier 1 Instruments

Date 24/07/2018

The European Banking Authority published today its reply to claims by Caius Capital LLP that the European Central Bank (ECB) has breached Union law by not disqualifying the Common Equity Tier 1 (CET1) classification of Unicredit capital instruments due to arrangements involving a transaction known as Convertible and Subordinated Hybrid Equity-Linked Securities (CASHES). The EBA finds that there is no clear evidence of a breach of Union law by the ECB and therefore decided not to open a formal investigation. 

China Life Pension Company Selects Style Analytics Enterprise As New Portfolio Style Analysis Platform - Style Analytics Strengthens Extension Into China With Enterprise Platform For Portfolio Style Analysis

Date 24/07/2018

Style Analytics, the provider of factor-based analysis software for investment professionals, today announces a strategic agreement with China Life Pension Company (CLPC), the largest pension fund in China and wholly owned subsidiary of China Life Insurance (Group) Company with approximately RMB 267 billion (over USD 41 billion) in assets under management. China Life Pension Company has signed a multi-year contract to use Style Analytics Enterprise as its new portfolio style analysis platform to deliver intuitive and transparent insights into equity fund style, risk and performance. 

EBA Replies To Claims Concerning Common Equity Tier 1 Classification Of UniCredit Capital Instruments

Date 24/07/2018

The European Banking Authority published today its reply to claims by Caius Capital LLP that the European Central Bank (ECB) has breached Union law by not disqualifying the Common Equity Tier 1 (CET1) classification of Unicredit capital instruments due to arrangements involving a transaction known as Convertible and Subordinated Hybrid Equity-Linked Securities (CASHES). The EBA finds that there is no clear evidence of a breach of Union law by the ECB and therefore decided not to open a formal investigation. 

Monetary Authority Of Singapore Issues Prohibition Orders Against Chan Seet Fun For Misappropriation Of Client Monies

Date 24/07/2018

The Monetary Authority of Singapore (MAS) has issued 4-year prohibition orders against Ms Chan Seet Fun for the misappropriation of client monies.

Shenzhen Stock Exchange Publicly Denounces Changsheng Bio-Technology

Date 24/07/2018

The State Drug Administration notified on July 15 that Changchun Changsheng Bio-technology Co., Ltd. (hereinafter as “Changchun Changsheng”), subsidiary of Changsheng Bio-technology Co. Ltd. (hereinafter as “the Company”), was found violating relevant laws and regulations while producing freeze-dried rabies vaccines for human use. According to the notification, the State Drug Administration has launched an investigation on Changchun Changsheng and found that the company has seriously violated the Criteria for Quality Control of Drug Manufacturing by falsifying production records for its freeze-dried human rabies vaccines. Its sales of freeze-dried human rabies vaccines account for nearly one fourth of the total amount in domestic market. The announcement has provoked serious concern among the media and consumers. Jilin Food and Drug Administration has revoked Changchun Changsheng’s Drug GMP Certificate, ordering the company to halt its rabies vaccine production. In addition, Changchun Changsheng's "Diphtheri, Tetanus and Acellular pertussis Combined Vaccine, Adsorbed” fails to meet the standards for biological potency; Jilin Food and Drug Administration have initiated a series of administrative penalties against Changchun Changsheng such as confiscation of inventories and unlawful proceeds and imposing fines.

External Report On Fees And Costs Disclosure Welcomed By ASIC

Date 24/07/2018

The Australian Securities and Investments Commission (ASIC) has today released the external report into Regulatory Guide 97 Fees and costs disclosure (RG 97) commissioned in November 2017.

Further Optimizing Corporate Governance Structure, And Duly Fulfilling The Front-Line Regulatory Responsibility - Shenzhen Stock Exchange Releases The Amended Charter

Date 24/07/2018

Recently, Shenzhen Stock Exchange (“SZSE”) issued an amended version of the Charter of Shenzhen Stock Exchange (hereinafter referred to as the "Charter").